Quince Therapeutics, Inc. (QNCX)
Nasdaq: QNCX · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Apr 10, 2026 | Mar 24, 2025 | Apr 1, 2024 | Mar 15, 2023 | Mar 1, 2022 | Mar 1, 2021 | Mar 16, 2020 | · |
| Research and development | 35,382 | 18,590 | 9,447 | 25,178 | 60,795 | 61,307 | 30,214 | 10,085 |
| General and administrative | 15,047 | 17,580 | 17,695 | 26,012 | 29,523 | 17,586 | 8,954 | 2,034 |
| Total operating expenses | 58,068 | 57,285 | 34,620 | 52,015 | 90,318 | 78,893 | 39,168 | 12,119 |
| Operating income | -58,068 | -57,285 | -34,620 | -52,015 | -90,318 | -78,893 | -39,168 | -12,119 |
| Interest expense | · | · | · | · | · | · | · | 957 |
| Interest and investment income | 1,244 | 2,929 | 3,478 | 1,068 | 620 | 2,044 | 2,188 | 806 |
| Other income (expense), net | 486 | -676 | -102 | -997 | -247 | 0 | 0 | · |
| Income before income taxes | -80,765 | -56,741 | -31,582 | -51,944 | -89,945 | -76,849 | -36,980 | · |
| Income tax expense | 3,214 | 87 | -197r | -284 | 0 | 0 | 0 | 0 |
| Net income including non-controlling interests | · | -56,828 | -31,385 | -51,660 | -89,945 | -76,849 | -36,980 | -12,476 |
| Net income | -83,979 | -56,828 | -31,385 | -51,660 | -89,945 | -76,849 | -36,980 | -12,476 |
| Earnings per share, basic | -1.68 | -1.31 | -0.84 | -1.54 | -3.03 | · | · | · |
| Earnings per share, diluted | -1.68 | -1.31 | -0.84 | -1.54 | -3.03 | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -3.03 | -2.63 | -1.94 | -3.71 |
| Weighted average shares, basic | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · |
| Weighted average shares, diluted | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 29,718,506 | 29,176,232 | 19,031,940 | 3,362,192 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InvestmentIncomeNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted